Last updated: February 25, 2026
What Are the Case Details?
Cephalon Inc. filed suit against Mylan Pharmaceuticals Inc. in the District of Delaware (Case No. 1:11-cv-00164) in January 2011. The dispute centers on patent infringement related to Cephalon’s market rights for a medication containing modafinil.
Case Timeline
- January 2011: Filing of complaint seeking declaratory judgment and asserting patent infringement.
- March 2011: Mylan responds, challenging patent validity and non-infringement.
- Late 2011 – Early 2012: Discovery phase, involving claim construction hearings.
- May 2012: Summary judgment motions filed.
- December 2012: District Court issues ruling.
Patent and Technology at Issue
Cephalon’s patent relates to formulations of modafinil, used for narcolepsy and sleep disorders. Mylan sought to market generic equivalents, prompting Cephalon to assert patent protections. Key patent claims cover specific formulations and methods of use for modafinil.
Court Ruling Summary
The District Court granted summary judgment in favor of Cephalon, holding that:
- The patent was valid.
- Mylan’s generic products infringed on Cephalon’s patent.
The ruling was based on the patent’s clear claims and the non-obviousness of the formulation. The court rejected Mylan’s challenges to patent validity, citing substantial evidence of novelty and non-obviousness.
Impact of the Decision
The ruling delayed regulatory approval of Mylan’s generic modafinil, preserving Cephalon’s market exclusivity for the patent’s term. This decision reflected the strength of Cephalon’s patent claims and their defensibility against validity challenges.
Subsequent Proceedings
- Injunctions: The court issued an injunction preventing Mylan from launching generic versions until patent expiry.
- Appeals: Mylan filed notices of appeal in 2013, contesting the validity and infringement rulings. The case remained active through 2015, with no final appellate decision.
- Settlement: No public records indicate a settlement; the case proceeded through litigation phases, ultimately favoring Cephalon.
Litigation Strengths and Weaknesses
| Strengths |
Weaknesses |
| Clear patent claims |
Challenges to patent validity by Mylan |
| Strong claim construction |
Potential prior art references limiting enforceability |
| Court’s emphasis on non-obviousness |
Market entry flexibility for competitors post-approvals |
Market and Legal Context
The case exemplifies patent enforcement strategies within the biopharmaceutical sector, especially for formulations with significant commercial value. It underscores the importance of patent claim scope and the risks of litigation challenges by generic manufacturers.
Key Legal Takeaways
- Patent validity challenges are common but require substantial supporting evidence.
- Claim construction significantly influences infringement and validity outcomes.
- Patent enforcement can effectively delay generic competition and sustain exclusivity.
- Courts favor patent validity when claims are clear and non-obvious, but challengers often leverage prior art.
- Settlement or licensing agreements are common but not publicly documented in this case.
Key Takeaways
Cephalon’s litigation against Mylan exemplifies robust patent enforcement to protect market share for high-value pharmaceuticals. The case reinforces the importance of clear patent claims and comprehensive validity defenses. Litigation outcomes can significantly impact generic entry timelines, influencing drug pricing and availability.
FAQs
Q1. Did Cephalon win the patent infringement case?
Yes. The District Court granted summary judgment favoring Cephalon, finding the patent valid and infringed.
Q2. Is this case typical of pharmaceutical patent disputes?
Yes. Patent disputes over formulations or methods and challenges to validity are common in the industry.
Q3. What was the primary legal hurdle for Mylan?
Proving patent invalidity was challenging due to the patent’s strong claims on formulation specifics and non-obviousness.
Q4. Did Mylan succeed in delaying generic entry?
The case prevented Mylan from launching generics until the patent expired, maintaining Cephalon’s exclusivity.
Q5. Were there any appeals or settlements?
Mylan filed appeals, but no final appellate outcomes or settlements are publicly documented.
References
- U.S. District Court for the District of Delaware. (2012). Cephalon Inc. v. Mylan Pharmaceuticals Inc., No. 1:11-cv-00164.
- Patent filing and prosecution records, USPTO.
- Public legal filings and case documentation, Westlaw.
